We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Perlegen Sciences and Mitsubishi Pharma have announced a licensing agreement
for the late-stage development and commercialization of MCC-555 (a peroxisome
proliferator activated receptor (PPAR) agonist) for the treatment of diabetes
and other metabolic disorders.
Pharmacopeia Drug Discovery has announced that Schering-Plough has decided to
initiate preclinical development of a novel small molecule drug candidate identified
as part of the companies' collaboration targeted at inflammatory disease.
Seattle Genetics has entered into a license agreement with Protein Design Labs
(PDL) for exclusive rights to PDL's anti-CD33 program for both unconjugated
antibody and antibody-drug conjugate (ADC) applications.
Millennium Pharmaceuticals has presented positive clinical results for Velcade
in treating patients across the multiple myeloma (MM) treatment paradigm, including
data regarding the use of Velcade as a single agent and in combination with
standard and emerging MM therapies.
Vion Pharmaceuticals has announced that a Phase I trial of its anticancer agent
Cloretazine (VNP40101M) in pediatric brain tumors had been initiated by the
Pediatric Brain Tumor Consortium.
Lorus Therapeutics has completed its Phase II trial of GTI-2040 in combination
with capecitabine in patients with advanced and metastatic renal cell carcinoma.
Two-year data from the AFFIRM Phase III monotherapy trial showed that treatment
with Tysabri led to a significant reduction in disability progression, the rate
of clinical relapses and brain lesions in patients with relapsing forms of multiple
sclerosis (MS).
Palatin Technologies has released data from preclinical studies of PT-15, the
Company's novel, small molecule, melanocortin receptor subtype-4 (MC4R) selective
agonist that is in development for the treatment of obesity.
Targeted Genetics has announced that Beverly Davidson of the University of Iowa
published encouraging preclinical results for a potential treatment of Huntington's
disease (HD).